From Intractable to Treatable: Milestones and Horizons in the Management of HER2+ Breast Cancer
Canadian Oncology Today · 2024
DOI: 10.58931/cot.2024.1222 ↗Kurz gefasst
Fachartikel in der Zeitschrift Canadian Oncology Today, 2024. Verfasst von Meredith Li und 1 weiteren Autor:innen. Die Arbeit nennt 17 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).
Abstract (Originalsprache)
The human epidermal growth factor receptor 2 (HER2) is a member of the epidermal growth factor receptor (EGFR) family that initiates various signalling pathways that control cell proliferation and tumourigenesis. Historically, approximately 15% of breast cancers have been characterized by overexpression or amplification of HER2, known as “HER2+” breast cancers. This subtype has been associated with an adverse prognosis, along with a high risk of recurrence and worse survival outcomes. However, with the discovery and subsequent development of HER2‑targeted therapies, the clinical course of HER2+ breast cancers has fundamentally changed. Optimizing therapeutic strategies using existing and emerging HER2-targeted therapies to build upon these advances remains a major priority for clinical development and treatment delivery. In 1998, the American Food and Drug Administration (FDA) and Health Canada approved trastuzumab, the first HER2-targeted therapy. Trastuzumab, a monoclonal antibody that binds to the HER2 receptor, has demonstrated clinical activity and improved outcomes in patients with metastatic HER2+ breast cancer when combined with chemotherapy. Following soon after, the first trial of adjuvant trastuzumab (HERA) demonstrated improvements in outcomes when combined with chemotherapy for early HER2+ breast cancer. More than 25 years after its first approval, trastuzumab retains a central role in the treatment of both early and advanced HER2+ breast cancer and has provided a backbone for both new therapeutic combinations (eg. with small molecule inhibitors of HER2) and new classes of therapeutic agents (antibody drug conjugates [ADC]). These successors of trastuzumab are currently redefining the HER2+ treatment landscape in both advanced and early breast cancer.
Zitieren
APA
Li, M., & Cescon, D. W. (2024). From Intractable to Treatable: Milestones and Horizons in the Management of HER2+ Breast Cancer. Canadian Oncology Today. https://doi.org/10.58931/cot.2024.1222
Vancouver
Li M, Cescon DW. From Intractable to Treatable: Milestones and Horizons in the Management of HER2+ Breast Cancer. Canadian Oncology Today. 2024. doi:10.58931/cot.2024.1222
BibTeX
@article{Li2024,
author = {Li, Meredith and Cescon, David W.},
title = {From Intractable to Treatable: Milestones and Horizons in the Management of HER2+ Breast Cancer},
journal = {Canadian Oncology Today},
year = {2024},
doi = {10.58931/cot.2024.1222}
}
EUVIMED